BUSINESS● ELEVATEDJun 27 · Jun 27, 2026, 4:28 PM
Why is the US targeting Germany's drug industry?
DW News [en]
A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS31m agoShort-Term Warehousing Solution introduced at BLR Logistics Park by AISATSThe HinduBUSINESS31m agoCommercial Metals Q3 2026 Earnings PreviewSeeking Alpha Tech